SL-1002 for Osteoarthritic Knee Pain
(COMPASS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an injectable medicine called SL-1002 to see if it can reduce knee pain in people with osteoarthritis. The study involves giving patients the medicine and observing the effects. The goal is to find out if a single injection can safely and effectively relieve pain.
Will I have to stop taking my current medications?
The trial does not specify that you must stop taking your current medications. However, if you are taking analgesics (pain relievers), you need to be on a stable dose for at least 6 weeks before the study and cannot change the dose during the study without approval from the study doctor.
Are You a Good Fit for This Trial?
Adults over 35 with a BMI of 18.0-40.0 kg/m2, experiencing knee pain from osteoarthritis for more than 6 months, and not responding to conservative treatments can join this trial. They must have moderate knee arthritis confirmed by imaging, stable medication use, and agree to contraception if applicable. Exclusions include inflammatory conditions like rheumatoid arthritis, recent joint injections or surgery on the knee, drug abuse history, significant heart or lab abnormalities.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase A
Single ascending dose escalation study with SL-1002 or placebo in 3 cohorts of 8 patients each
Treatment Phase B
Randomized treatment with SL-1002 or placebo at recommended dose from Phase A
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SL-1002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Saol Therapeutics Inc
Lead Sponsor